Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 envelope glycoprotein gp120 V1V2 apex is a critical structural domain located at the distal tip of the trimeric envelope (Env) spike, which serves as the sole target for neutralizing antibodies on the virus surface [UniProt P04578]. This apex is formed by the association of the first and second variable loops (V1 and V2) from three gp120 subunits, creating a complex quaternary epitope characterized by both protein residues and conserved N-linked glycans [McLellan et al., Nature 2011]. Biologically, the V1V2 apex is essential for maintaining the Env trimer in its pre-fusion closed conformation, thereby shielding the core of the protein from immune recognition until it encounters the CD4 receptor [Julien et al., Science 2013]. In the progression of HIV-1 infection, the virus utilizes the high mutability of the V1V2 loops to escape host immune pressure, making this region a key determinant of viral fitness and neutralization sensitivity [NIH/NIAID]. Therapeutic strategies focus on this site because it is the target of potent broadly neutralizing antibodies (bNAbs) like PG9 and PGT145, which can neutralize a wide range of global HIV-1 isolates [Sok et al., Science 2014]. These bNAbs typically utilize long, anionic heavy-chain loops to penetrate the glycan shield and bind the underlying conserved protein scaffold, effectively blocking viral entry into host cells [PubMed PMC4289608].
Broadly neutralizing antibodies bind to the quaternary V1V2 apex, stabilizing the pre-fusion closed state of the Env trimer and sterically hindering the interaction with the CD4 receptor, thereby preventing viral entry [McLellan et al., Nature 2011; PubMed PMC4289608].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunodeficiency virus type 1 envelope glycoprotein gp120 V1V2 apex (HIV-1 gp120 V1V2 apex) (HIV-1 gp120 V1V2 apex).